Figure 5. Effectiveness of HS in inhibiting prion replication.

ASA showing the kinetics of MoPrP fibrillization in the presence of 1 µg/mL of HS (A) and the corresponding mean value of the lag phases (in hours) for MoPrP treated with HS (**P<0.01) (B). In (C) Western-blot results showing the dose-dependent removal of PrP^Sc from ScGT1 cells. In the upper panel, total PrP expression detected by immunoblotting after the addition of increasing concentrations of HA and FA (here used as non-PK controls); the lower panel shows PrP^Sc levels after digestion with PK.